US 12,378,311 B2
Anti-MARCO antibodies and uses thereof
Nadine Jahchan, San Carlos, CA (US); Michel Streuli, Atherton, CA (US); Xi Yang, Hillsborough, CA (US); Linda Liang, Mountain View, CA (US); Venkataraman Sriram, Berkeley, CA (US); Joshua Pollack, Richmond, CA (US); Kara Mojica, Dublin, CA (US); Vladislava Juric, San Mateo, CA (US); Linnea Haeggblom, San Francisco, CA (US); Leonard G. Presta, San Francisco, CA (US); and Sayantan Mitra, Mountain View, CA (US)
Assigned to Portsmouth Merger Sub II, LLC, Boston, MA (US)
Filed by Portsmouth Merger Sub II, LLC, Boston, MA (US)
Filed on Dec. 19, 2022, as Appl. No. 18/068,237.
Application 18/068,237 is a division of application No. 17/529,927, filed on Nov. 18, 2021, granted, now 11,572,407.
Claims priority of provisional application 63/244,662, filed on Sep. 15, 2021.
Claims priority of provisional application 63/115,272, filed on Nov. 18, 2020.
Prior Publication US 2024/0084000 A1, Mar. 14, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01)] 31 Claims
 
1. A method of treating cancer in a subject, comprising administering to the subject an antibody or antigen binding fragment thereof that binds to human MARCO (SEQ ID NO: 384) comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a light chain comprising a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein:
a. CDR-H1 comprises the sequence GFSLTSYHVS (SEQ ID NO: 2),
b. CDR-H2 comprises the sequence AIWTGGSIA (SEQ ID NO: 3),
c. CDR-H3 comprises the sequence DLSDYYSSYTSFDY (SEQ ID NO: 4),
d. CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431) or XASEGISNDLA (SEQ ID NO: 383), wherein X is arginine (R) or leucine (L),
e. CDR-L2 comprises the sequence AASRLQS (SEQ ID NO: 528) or AASRLQD (SEQ ID NO: 8), and
f. CDR-L3 comprises the sequence QQSYKYPLT (SEQ ID NO: 9).